Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Nonoperative Management (NOM) and Organ Preservation First Strategy (OPFS) Versus Radical Operation (RO) for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers: A Single-Center, Bidirectional Registry Study

NCT07642323 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07642323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07642323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Nonoperative Management (NOM) and Organ Preservation First Strategy (OPFS) Versus Radical Operation (RO) for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers: A Single-Center, Bidirectional Registry Study
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
January 15, 2030
Enrollment
22 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancers, gastrointestinal cancers - anus, gastrointestinal cancers - colorectal, gastrointestinal cancers - stomach